Published on
June 3, 2022

TripSitter.Clinic Launches New App for At-Home Ketamine Therapy

TORONTO, June 3, 2022 /CNW/ - TripSitter Clinic Ltd. (CSE: KETA) (FSE: UY0) ("TripSitter" or the "Company"), today announced the official launch of the TripSitter App, a simple and free App that makes it easy for users to access TripSitter Clinics' services.

CEO of TripSitter Clinic, Dr. Huber stated: "we are delighted to announce our new App launch which will enable users with a convenient platform for patients to connect to a doctor, and then be guided along their psychedelic healing journey with specially trained Tripsitters.

The App is available to users through Apple's App Store and Google's Play Store.  App features a compatibility assessment so patients will be matched with Tripsitters that share common interests and personalities.  The App features secure telehealth and unlimited messaging between patients and their Tripsitter and also enables scheduling, medication tracking, and billing

TripSitter Clinic is currently operating in Alabama, Arizona, California , Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Michigan, Minnesota, Mississippi, Montana, Nebraska, New Hampshire, New York, North Dakota, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming with continued expansion across the United States over the next 6 months.


TripSitter Clinic LTD., through its wholly-owned subsidiary TripSitter Clinic Corp, is at the forefront of two emerging sectors: telehealth and psychedelic medicine. The Company's consultative virtual clinic, TripSitter.Clinic, is an internationally-recognized SaaS platform that provides care, monitoring, and coaching while connecting patients with licensed physicians in the United States who can evaluate for a prescribed psychedelic treatment program of therapeutic low-dose ketamine medication. TripSitter is not a primary care physician (PCP). TripSitter.Clinic requires prospective patients to provide a diagnosis from their PCP along with other health information to their chosen TripSitter physician during the initial intake process. When a patient is approved for treatment by their physician, TripSitter.Clinic connects the patient with experts who also use the platform to consult and coordinate with the patient and their physician. Learn more at


Dr. John Huber, CEO

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

Disclaimer for Forward-Looking Information

This news release includes certain forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Forward-looking information in this news release includes statements concerning the Company's general business plans, the tele-health industry and the Company's market position within it, and statements concerning the listing of the Company's common shares on the CSE. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors that could materially affect such forward-looking information are described in the risk factors in the Company's final long-form prospectus dated November 22, 2021, and the schedules attached thereto, that are available on the Company's profile on SEDAR at Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.